Inspire Medical Systems filings document formal disclosures for a medical technology company commercializing neurostimulation therapy for obstructive sleep apnea. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information, Regulation FD presentation materials, tax-related events and officer or compensation matters.
Proxy and annual-meeting filings describe director elections, stockholder voting, executive compensation, equity incentive plan authorization and governance provisions, including charter and bylaw matters. These records also disclose common stock award reserves and the governance framework for a company selling Inspire therapy through hospitals and ambulatory surgery centers.
BlackRock, Inc. filed an amended Schedule 13G reporting a passive ownership stake in Inspire Medical Systems (INSP). As of September 30, 2025, BlackRock beneficially owned 3,353,407 shares of INSP, representing 11.3% of the common stock. The filing lists sole voting power over 3,283,122 shares and sole dispositive power over 3,353,407 shares, with no shared voting or dispositive power.
BlackRock certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing notes that iShares Core S&P Small-Cap ETF has an interest in INSP common stock that is more than five percent of the total outstanding shares.
Inspire Medical Systems (INSP) reported an insider transaction by a director. On 10/14/2025, the director acquired 229 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy. After this transaction, the director beneficially owns 3,986 shares, held directly.
Inspire Medical Systems (INSP) director Casey M. Tansey reported an equity award. On 10/14/2025, Tansey acquired 221 shares of common stock at $78.84 per share, received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy.
Following this transaction, Tansey beneficially owned 22,235 shares directly. Additional indirect holdings reported include 500 shares held by The Kimberly Tansey Irrevocable Trust and 500 shares held by The Kylie Tansey Irrevocable Trust.
Inspire Medical Systems (INSP) director Gary L. Ellis reported acquiring 372 shares of common stock on October 14, 2025. The shares were received in lieu of cash fees under the company’s Non-Employee Director Compensation Policy, at a reported price of $78.84 per share.
Following this transaction, Ellis beneficially owns 6,454 shares, held directly. This filing reflects routine director compensation settled in stock rather than cash.
Inspire Medical Systems (INSP) reported an insider equity award. Director Shelley G. Broader acquired 245 shares of common stock on 10/14/2025 at $78.84 per share. The shares were received in lieu of cash fees under the company's Non-Employee Director Compensation Policy.
After this transaction, Broader’s beneficial ownership stands at 4,367 shares, held directly.
Inspire Medical Systems, Inc. filed a current report describing upcoming investor and analyst meetings in October 2025. The company is using a prepared slide presentation for these meetings, which is furnished as Exhibit 99.2 and made available on its investor relations website.
The filing also lists a related press release as Exhibit 99.1. The company clarifies that the presentation materials and related disclosure are furnished, not filed, so they are not subject to certain Exchange Act liability provisions or automatically incorporated into other securities law filings.
FMR LLC and Abigail P. Johnson filed Amendment No. 4 to a Schedule 13G reporting ownership of common stock of Inspire Medical Systems, Inc. The filing shows an aggregate beneficial ownership of 741,312.10 shares, representing 2.5% of the outstanding common stock. FMR LLC reports sole voting power of 739,599 shares and sole dispositive power of 741,312.10 shares; Abigail P. Johnson reports sole dispositive power of 741,312.10 shares and no voting power. The filers certify the shares are held in the ordinary course of business and not for the purpose of changing control. The filing includes referenced exhibits and powers of attorney.
Citadel and related entities reported ownership stakes in Inspire Medical Systems (INSP). The joint Schedule 13G shows Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC each may be deemed to beneficially own 1,379,861 shares representing 4.7% of outstanding common stock. Citadel Securities LLC reported 114,245 shares (0.4%), and Citadel Securities Group LP and Citadel Securities GP LLC each reported 333,181 shares (1.1%). Mr. Kenneth Griffin is reported with shared beneficial ownership of 1,713,042 shares (5.8%). The filing states holdings are as of the market open on 10/06/2025 and uses a share base of 29,574,316 shares for percentage calculations.
Richard Buchholz, Chief Financial Officer and Director of Inspire Medical Systems, Inc. (INSP), reported an insider sale on 08/29/2025 of 11,000 shares of common stock at a price of $93.39 per share. After the sale, Mr. Buchholz beneficially owned 44,867 shares (direct). The filing also discloses indirect holdings of 1,475 shares each held by his daughter and three sons. The Form 4 was signed by an attorney-in-fact on 09/02/2025.
Inspire Medical Systems (INSP) filed a Form 144 notifying a proposed sale of 11,000 common shares through RBC Capital Markets on 08/29/2025 on the NYSE, with an aggregate market value of $1,027,349.00. The filing reports 29,574,316 shares outstanding, so the proposed block represents roughly 0.04% of outstanding shares. All 11,000 shares were acquired by option exercise between 06/30/2019 and 10/09/2020, totaling the same 11,000 shares listed for sale. No securities were sold by the filer in the past three months, and the filer certifies no undisclosed material adverse information.